Clinical Trials Underway into Immunotherapies for Crohn’s Disease and Ulcerative Colitis

Clinical Trials Underway into Immunotherapies for Crohn’s Disease and Ulcerative Colitis
Qu Biologics Inc. recently provided an update for ongoing clinical trials assessing the company’s lead candidate for inflammatory bowel diseases (IBD), namely ulcerative colitis and Crohn’s disease. The company also announced it has closed an oversubscribed private funding of 3.5 million Canadian dollars, bringing its total private equity capital raised to 19 million dollars. Qu Biologics is a biotechnology

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Ken Murphy, M.D. says:

    I am a 67 year old semiretired physician with crohn’s with a question about availability of your SSI drug. My research leads me to believe your approach is on the right tract. I have avoided standard immune suppressive meds despite recommendations to try these meds due to my belief that my problem is innate immune system disability. I do have an autophagy genetic polymorphism. I am wondering when your SSI will be available.

Leave a Comment

Your email address will not be published. Required fields are marked *